drugset / Trial / NCT00391898

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

NCT00391898

Phase 4 Completed 95 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The study evaluated the efficacy of levodopa/carbidopa/entacapone vs levodopa/carbidopa in patients with Parkinson's disease and early wearing-off with levodopa

Timeline

Start
2006-10
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Entacapone Small molecule 200 mg Oral
Background Carbidopa Unknown 25 mg Oral
Background Carbidopa Unknown 37.5 mg Oral
Background Levodopa Small molecule 100 mg Oral
Background Levodopa Small molecule 150 mg Oral

Indications